Clinical Trial: Treatment Of Impetigo With Topical SB-275833 Ointment, 1% Versus Topical Placebo Ointment

Study Status: Completed
Recruit Status: Completed
Study Type: Interventional

Official Title: A Randomised, Double-blind, Multicentre, Superiority Placebo-controlled, Phase III Study to Assess the Efficacy and Safety of Topical 1% SB-275833 Ointment Versus Placebo Ointment Applied Twice Daily

Brief Summary: The goal of this study is to determine if topical SB-275833 ointment, 1% is more effective than a placebo ointment in the treatment of primary impetigo.

Detailed Summary:
Sponsor: GlaxoSmithKline

Current Primary Outcome: Clinical response of impetigo at end of therapy visit. Clinical response of success is defined as no further need for antibacterial treatment.

Original Primary Outcome: Same as current

Current Secondary Outcome: Clinical response of impetigo at follow up visit. Impetigo lesion area at end of therapy and follow up visits.

Original Secondary Outcome: Same as current

Information By: GlaxoSmithKline

Dates:
Date Received: August 22, 2005
Date Started: April 2005
Date Completion:
Last Updated: September 22, 2016
Last Verified: September 2016